Hospital
Ihc Health Services, INC.
Ihc Health Services, INC. was paid $65.78M by Medicaid between Jan 2018 and Dec 2024, across 360 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 69% of everything it billed.
33Billing provider infoIHC HEALTH SERVICES, INC.
ST GEORGE, UT 84790
ST GEORGE, UT 84790
33aNPI1366452880assigned 08/08/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$65.78M
24GClaims911,010
24DCodes billed360
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Utah
Rank by total paid#2 of 6
Median peer was paid$19.91M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, DENIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 135,415 | $8.28M | |
| 2019 | 149,439 | $9.76M | |
| 2020 | 165,953 | $12.84M | |
| 2021 | 213,482 | $16.60M | |
| 2022 | 189,939 | $15.83M | |
| 2023 | 39,435 | $1.64M | |
| 2024incomplete | 17,347 | $821K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 69% | 77,752 | 32,573 | $45.20M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 62,735 | 49,117 | $1.77M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 30,068 | 25,171 | $1.77M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.4% | 4,562 | 3,518 | $1.56M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.1% | 22,070 | 19,386 | $1.37M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 24,581 | 19,021 | $1.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.5% | 13,718 | 11,173 | $1.01M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 7,013 | 6,146 | $780K |
| 80050 | General health panel | <1% | 7,941 | 7,245 | $625K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,014 | 3,655 | $389K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,890 | 1,684 | $365K |
| 78431 | <1% | 363 | 341 | $323K |
348 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,732 | $270K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,913 | $234K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,105 | $223K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,908 | $222K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,732 | $215K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,188 | $202K |
| 85027 | <1% | 5,696 | $201K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,936 | $193K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,819 | $183K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,834 | $183K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 983 | $180K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,018 | $169K |
| 80053 | Comprehensive metabolic panel | <1% | 57,740 | $169K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,721 | $165K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,549 | $161K |
| 80081 | <1% | 2,070 | $161K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,024 | $154K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,214 | $154K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,132 | $139K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,699 | $127K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,409 | $114K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,814 | $113K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,795 | $111K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,674 | $110K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 974 | $106K |
| 81001 | <1% | 25,055 | $104K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,302 | $95K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,717 | $95K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,968 | $94K |
| 73630 | <1% | 1,612 | $93K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,663 | $88K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,499 | $87K |
| 93325 | <1% | 534 | $84K | |
| 97602 | <1% | 1,596 | $84K | |
| 72141 | <1% | 589 | $83K | |
| 73110 | <1% | 1,398 | $81K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,621 | $80K |
| 73610 | <1% | 1,466 | $79K | |
| 74018 | <1% | 1,627 | $79K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 835 | $79K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,537 | $78K |
| 73130 | <1% | 1,166 | $78K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,439 | $77K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,304 | $75K |
| J2704 | Injection, propofol, 10 mg | <1% | 11,424 | $75K |
| G0378 | Hospital observation service, per hour | <1% | 780 | $72K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 972 | $72K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 378 | $67K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,048 | $67K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 444 | $66K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,875 | $65K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,844 | $65K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,316 | $64K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 86 | $64K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,287 | $64K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 482 | $64K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,685 | $59K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,279 | $58K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,065 | $57K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,862 | $56K |
| 73562 | <1% | 1,510 | $55K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,709 | $55K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,093 | $54K |
| 95812 | <1% | 278 | $53K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 686 | $53K |
| 72100 | <1% | 1,239 | $52K | |
| 73030 | <1% | 1,373 | $52K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,502 | $50K |
| 87070 | <1% | 3,087 | $49K | |
| 87186 | <1% | 4,783 | $49K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 765 | $48K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 72 | $48K |
| 87081 | <1% | 3,841 | $47K | |
| 86901 | <1% | 2,127 | $46K | |
| 81025 | <1% | 2,498 | $44K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,887 | $43K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,749 | $43K |
| 73080 | <1% | 538 | $42K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,956 | $42K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 473 | $41K |
| 76770 | <1% | 696 | $39K | |
| 81003 | <1% | 2,990 | $38K | |
| 85610 | <1% | 8,391 | $36K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,627 | $35K |
| 87507 | <1% | 367 | $34K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,217 | $34K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,773 | $33K |
| 97162 | <1% | 774 | $32K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,518 | $32K |
| 72110 | <1% | 468 | $31K | |
| 84702 | <1% | 10,224 | $30K | |
| 84481 | <1% | 2,150 | $30K | |
| 96376 | <1% | 3,657 | $29K | |
| 80061 | Lipid panel | <1% | 7,764 | $28K |
| 94729 | <1% | 206 | $26K | |
| 93971 | <1% | 929 | $26K | |
| 73140 | <1% | 361 | $26K | |
| C1769 | Guide wire | <1% | 1,267 | $26K |
| 0482T | <1% | 59 | $25K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 164 | $25K |
| 86850 | <1% | 1,757 | $24K | |
| 97161 | <1% | 203 | $23K | |
| 87631 | <1% | 379 | $23K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 169 | $22K |
| 76642 | <1% | 616 | $21K | |
| 88342 | <1% | 935 | $21K | |
| 82247 | <1% | 3,126 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,400 | $21K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,645 | $21K |
| 84439 | <1% | 5,111 | $20K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 392 | $19K |
| 83605 | <1% | 12,096 | $19K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 858 | $19K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 209 | $17K |
| 73221 | <1% | 120 | $17K | |
| 84466 | <1% | 2,560 | $16K | |
| 73090 | <1% | 225 | $16K | |
| 76536 | <1% | 206 | $16K | |
| 84403 | <1% | 1,326 | $15K | |
| 83690 | <1% | 14,807 | $15K | |
| 83735 | <1% | 8,218 | $15K | |
| 73502 | <1% | 481 | $14K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 297 | $14K |
| 70486 | <1% | 247 | $14K | |
| 76801 | <1% | 807 | $14K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,584 | $13K |
| 72170 | <1% | 268 | $13K | |
| 92526 | <1% | 235 | $13K | |
| 73590 | <1% | 258 | $13K | |
| 86003 | <1% | 682 | $13K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,747 | $12K |
| 72040 | <1% | 306 | $12K | |
| 84550 | <1% | 1,362 | $12K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 518 | $11K |
| 0001A | <1% | 377 | $11K | |
| 0002A | <1% | 350 | $11K | |
| 82330 | <1% | 955 | $11K | |
| 80076 | <1% | 808 | $11K | |
| 77066 | Tomosynthesis, mammo | <1% | 88 | $10K |
| 82784 | <1% | 1,720 | $10K | |
| 83516 | <1% | 1,030 | $10K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 886 | $10K |
| 76830 | Ultrasound, transvaginal | <1% | 499 | $10K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 75 | $10K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,936 | $9K |
| 87077 | <1% | 1,617 | $9K | |
| 85379 | <1% | 4,209 | $9K | |
| 94060 | <1% | 139 | $8K | |
| 71250 | <1% | 133 | $8K | |
| 70491 | <1% | 58 | $8K | |
| 72082 | <1% | 90 | $8K | |
| 93017 | <1% | 548 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,516 | $7K |
| 84484 | <1% | 8,962 | $7K | |
| 88304 | <1% | 805 | $7K | |
| 82607 | <1% | 4,176 | $7K | |
| 12001 | <1% | 273 | $7K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 312 | $7K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 239 | $7K |
| 59025 | Fetal non-stress test | <1% | 355 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,371 | $7K |
| 86140 | <1% | 5,824 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 187 | $6K |
| 12011 | <1% | 148 | $6K | |
| 78227 | <1% | 29 | $6K | |
| 85651 | <1% | 5,207 | $6K | |
| 83880 | <1% | 3,022 | $6K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 32 | $5K |
| 86480 | <1% | 331 | $5K | |
| 70498 | <1% | 96 | $5K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 76 | $5K |
| J3490 | Unclassified drugs | <1% | 395 | $5K |
| 86364 | <1% | 88 | $5K | |
| 0450 | Emergency room services | <1% | 127 | $5K |
| 84703 | <1% | 2,786 | $5K | |
| 82570 | <1% | 2,563 | $5K | |
| 87040 | <1% | 2,914 | $4K | |
| 86431 | <1% | 745 | $4K | |
| 89060 | <1% | 68 | $4K | |
| 82550 | <1% | 1,972 | $4K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 214 | $4K |
| 92523 | <1% | 30 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $4K |
| 87522 | Neg quan hep c or qual rna | <1% | 154 | $4K |
| 82670 | <1% | 631 | $4K | |
| 82805 | <1% | 278 | $4K | |
| 82728 | <1% | 2,879 | $4K | |
| 83970 | <1% | 1,048 | $4K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 27 | $4K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,396 | $4K |
| 87088 | <1% | 3,877 | $4K | |
| 84100 | <1% | 1,933 | $3K | |
| 88307 | <1% | 198 | $3K | |
| 86803 | <1% | 1,341 | $3K | |
| 82565 | <1% | 1,104 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,478 | $3K |
| 72146 | <1% | 41 | $3K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 431 | $3K |
| 84144 | <1% | 430 | $3K | |
| 83520 | <1% | 217 | $3K | |
| 82043 | <1% | 1,952 | $3K | |
| 84402 | <1% | 152 | $3K | |
| 80074 | <1% | 282 | $3K | |
| 83540 | <1% | 2,880 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,535 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 64 | $3K |
| 86787 | <1% | 590 | $2K | |
| 87075 | <1% | 393 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 90 | $2K |
| 83615 | <1% | 1,256 | $2K | |
| 86900 | <1% | 1,532 | $2K | |
| 86038 | <1% | 994 | $2K | |
| 72050 | <1% | 13 | $2K | |
| 0031A | <1% | 76 | $2K | |
| 84153 | <1% | 432 | $2K | |
| 84270 | <1% | 202 | $2K | |
| 86592 | <1% | 272 | $2K | |
| 82950 | <1% | 1,501 | $2K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 29 | $2K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 85 | $2K |
| 0064U | <1% | 13 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 733 | $2K |
| 95806 | <1% | 13 | $2K | |
| 84156 | <1% | 380 | $2K | |
| 85007 | <1% | 803 | $2K | |
| 82947 | <1% | 189 | $2K | |
| 97166 | <1% | 58 | $1K | |
| 85730 | <1% | 1,349 | $1K | |
| 71101 | <1% | 14 | $1K | |
| 83001 | <1% | 439 | $1K | |
| 82731 | <1% | 26 | $1K | |
| 86780 | <1% | 279 | $1K | |
| 12002 | <1% | 27 | $1K | |
| 78492 | <1% | 59 | $1K | |
| 86235 | <1% | 86 | $1K | |
| 74019 | <1% | 14 | $1K | |
| 76870 | <1% | 26 | $1K | |
| 93226 | <1% | 27 | $955.76 | |
| 72131 | <1% | 73 | $948.55 | |
| 0100U | <1% | 29 | $942.35 | |
| 88312 | <1% | 13 | $924.93 | |
| 84146 | <1% | 189 | $779.03 | |
| J1815 | Injection, insulin, per 5 units | <1% | 274 | $767.87 |
| 87660 | <1% | 12 | $711.04 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $710.05 |
| 82746 | <1% | 859 | $707.21 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 82 | $693.41 |
| 86812 | <1% | 53 | $661.76 | |
| 86376 | <1% | 399 | $654.19 | |
| 88331 | <1% | 22 | $636.15 | |
| 72072 | <1% | 12 | $636.04 | |
| 86160 | <1% | 71 | $621.40 | |
| 80047 | <1% | 94 | $610.21 | |
| 82140 | <1% | 148 | $596.72 | |
| 36591 | <1% | 86 | $579.12 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 28 | $561.30 |
| 43235 | <1% | 29 | $529.27 | |
| 93970 | <1% | 12 | $510.59 | |
| 88341 | <1% | 98 | $476.90 | |
| 87340 | <1% | 469 | $471.88 | |
| 93321 | <1% | 13 | $461.92 | |
| 82785 | <1% | 26 | $458.10 | |
| 86800 | <1% | 324 | $454.16 | |
| 70496 | <1% | 95 | $447.01 | |
| 86200 | <1% | 166 | $440.07 | |
| 93320 | <1% | 137 | $394.62 | |
| 91300 | <1% | 27 | $385.30 | |
| 83002 | <1% | 103 | $365.16 | |
| 90715 | <1% | 225 | $331.48 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 43 | $325.24 |
| 29125 | <1% | 52 | $320.09 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 137 | $319.76 |
| 86706 | <1% | 71 | $272.37 | |
| 72070 | <1% | 12 | $267.38 | |
| 97014 | <1% | 424 | $259.18 | |
| 88302 | <1% | 36 | $249.36 | |
| 87449 | <1% | 98 | $238.50 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 656 | $237.04 |
| 82951 | <1% | 12 | $233.20 | |
| 86677 | <1% | 122 | $224.19 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 16 | $223.84 |
| 82533 | <1% | 77 | $197.05 | |
| 86225 | <1% | 33 | $168.15 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 14 | $157.27 |
| 87338 | <1% | 13 | $156.04 | |
| 80069 | <1% | 59 | $148.06 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 335 | $136.74 |
| 87147 | <1% | 292 | $107.95 | |
| 82248 | <1% | 136 | $99.36 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 45 | $96.54 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 161 | $91.23 |
| 93976 | <1% | 46 | $87.76 | |
| 80178 | <1% | 46 | $86.35 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 14 | $78.85 |
| 84132 | <1% | 187 | $71.99 | |
| 84145 | <1% | 111 | $61.84 | |
| 90686 | <1% | 140 | $51.74 | |
| 84480 | <1% | 50 | $47.21 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 121 | $46.67 |
| 84460 | <1% | 26 | $43.27 | |
| 84478 | <1% | 55 | $35.40 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 23 | $35.33 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 435 | $34.19 |
| 78434 | <1% | 363 | $27.03 | |
| 84436 | <1% | 119 | $25.57 | |
| 83721 | <1% | 15 | $22.30 | |
| 83525 | <1% | 16 | $15.60 | |
| 85014 | <1% | 14 | $12.71 | |
| 81015 | <1% | 13 | $9.07 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 24 | $7.02 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 16 | $1.28 |
| 86704 | 0% | 15 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 348 | $0.00 |
| 86308 | 0% | 14 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 17 | $0.00 |
| 82952 | 0% | 12 | $0.00 | |
| 82378 | 0% | 66 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 32 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 32 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 23 | $0.00 |
| 78499 | 0% | 59 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 19 | $0.00 |
| 96415 | 0% | 20 | $0.00 | |
| 87480 | 0% | 12 | $0.00 | |
| 87510 | 0% | 12 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| 74420 | 0% | 13 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 13 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 20 | $0.00 |
| 93225 | 0% | 13 | $0.00 | |
| 96417 | 0% | 102 | $0.00 | |
| 82627 | 0% | 12 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 55 | $0.00 |
| 96367 | 0% | 114 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 24 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 16 | $0.00 |
| 84450 | 0% | 28 | $0.00 | |
| 94726 | 0% | 15 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 30 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 69 | $0.00 |
| 80164 | 0% | 28 | $0.00 | |
| 82010 | 0% | 14 | $0.00 | |
| 84165 | 0% | 13 | $0.00 | |
| 87324 | 0% | 29 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 24 | $0.00 |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 15 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
| 85045 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, DENIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ihc Health Services, INC. | Murray, UT | $68.77M |
| Ihc Health Services INC | Ogden, UT | $54.08M |
| Ihc Health Services, INC. | Provo, UT | $44.35M |
| Ihc Health Services INC | Logan, UT | $25.34M |
| Ihc Health Services, INC. | Cedar City, UT | $20.40M |
| Ihc Health Services, INC. | Salt Lake City, UT | $19.91M |
| Ihc Health Services, INC. | American Fork, UT | $17.19M |
| Ihc Health Services INC | Riverton, UT | $15.31M |
| Ihc Health Services INC | Sandy, UT | $11.66M |
| Ihc Health Services, INC. | Layton, UT | $11.61M |
| Ihc Health Services, INC. | Burley, ID | $5.14M |
| Ihc Health Services INC | Murray, UT | $4.64M |
| Ihc Health Services INC | St George, UT | $4.35M |
| Ihc Health Services INC | Heber City, UT | $4.31M |
| Ihc Health Services, INC. | Orem, UT | $4.18M |
| Ihc Health Services, INC. | Richfield, UT | $3.87M |
| Ihc Health Services INC | Tremonton, UT | $3.55M |
| Ihc Health Services, INC. | Spanish Fork, UT | $3.49M |
| Ihc Health Services INC | Park City, UT | $2.53M |
| Ihc Health Services, INC. | Mt Pleasant, UT | $2.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.